Literature DB >> 27980412

Complete blood cell count components and coronary slow-flow phenomenon.

Nasim Arjmand1, Mohammad Reza Dehghani1.   

Abstract

Entities:  

Year:  2016        PMID: 27980412      PMCID: PMC5144915          DOI: 10.2147/TCRM.S121433

Source DB:  PubMed          Journal:  Ther Clin Risk Manag        ISSN: 1176-6336            Impact factor:   2.423


× No keyword cloud information.
Dear editor Despite the implementation of preventive strategies, ischemic heart disease and stroke remain the main causes of mortality and morbidity worldwide.1,2 Of the cardiovascular diseases, coronary slow-flow phenomenon (CSFP), with a prevalence rate of 1%–7% among patients undergoing diagnostic coronary angiography, has been found to be associated with cardiovascular events, including cardiac arrhythmia and acute coronary syndrome.3–5 However, the potential mechanisms involved in the pathogenesis of CSFP remain unknown. Microvascular and endothelial dysfunctions, inflammation, diffuse atherosclerosis, and increased platelet aggregability have been reported to be the main possible etiologies for CSFP.6,7 We read the article by Altas et al8 regarding the relationship between the eosinophil count and the CSFP with great interest. They showed that of the complete blood count components (white blood cells, neutrophils, eosinophils, hemoglobin, and platelets), eosinophils were associated with the CSFP. In this study, eosinophil count was found to be elevated in patients with the CSFP compared with those with normal coronary arteries. In addition, higher eosinophil count was directly correlated with thrombolysis in myocardial infarction frame count in the CSFP group. When interpreting this study, we should consider some points which are of great importance. Biomarkers are used as diagnostic tools for risk stratification of cardiovascular diseases, of which complete blood cell count components have been shown to be a good and easily available predictor of cardiovascular events, particularly among patients with coronary artery disease.9 In addition to ischemic heart diseases, complete blood cell count components have also been found to be associated with the presence of CSFP; however, study results have been inconsistent in the literature. Several reports have demonstrated that the mean platelet volume is higher in patients with CSFP compared to individuals with normal coronary arteries;10–12 however, in one study the elevated mean platelet volume has not been associated with CSFP.13 Other platelet volume indices, including platelet distribution width and platelet–large cell ratio, have been associated with the presence of CSFP.6 On the other hand, the relationship between leukocyte subtypes and the CSFP has been inconsistent in previous studies. In most of the studies, total white blood cell count has not been the predictor of CSFP.6,13–15 In contrast, Akboga et al16 found that a higher white blood cell count is associated with CSFP. Regarding the red blood cell subtypes, results have also been diverse among studies. Two studies demonstrated that red cell distribution width correlated with the presence of CSFP,15,17 while in one study it did not.6 Furthermore, the elevated levels of hemoglobin11 and hematocrit15 have been associated with the CSFP. In addition to these regular complete blood cell count components, some novel biomarkers have also been found to be associated with the CSFP, including elevated neutrophil-to-lymphocyte ratio,14 increased platelet-to-lymphocyte ratio,16 and decreased lymphocyte-to-monocyte ratio.18 All these novel biomarkers are inflammation-based and have been useful in diagnosing other inflammatory diseases. White blood cell to mean platelet volume ratio is another novel biomarker examined in coronary artery disease and metabolic syndrome,19,20 which may be useful to detect the presence of CSFP as well. Given the findings of previous studies, it is likely that the two main pathophysiologic mechanisms involved in the development of CSFP may include the enhancement of inflammation status and thrombogenesis. However, due to inconsistent results with regard to the biomarkers, further studies are required to elucidate the pathogenesis of this phenomenon. In addition, the inconsistent findings regarding the complete blood cell count may be explained by the notion that the prevalence of CSFP is low and the majority of studies included small sample sizes. Further large-scale studies, including all these parameters in the final analysis, can clarify this inconsistency.
  20 in total

1.  Aborted sudden cardiac death in a 20-year-old man with slow coronary flow.

Authors:  Basri Amasyali; Hasan Turhan; Sedat Kose; Turgay Celik; Atila Iyisoy; Hurkan Kursaklioglu; Ersoy Isik
Journal:  Int J Cardiol       Date:  2005-07-27       Impact factor: 4.164

Review 2.  Microvascular angina and the continuing dilemma of chest pain with normal coronary angiograms.

Authors:  Richard O Cannon
Journal:  J Am Coll Cardiol       Date:  2009-09-01       Impact factor: 24.094

3.  Increased platelet activation in patients with slow coronary flow.

Authors:  Turgay Celik; U Cagdas Yuksel; Baris Bugan; Atila Iyisoy; Murat Celik; Sait Demirkol; Halil Yaman; Hurkan Kursaklioglu; Selim Kilic; Ersoy Isik
Journal:  J Thromb Thrombolysis       Date:  2010-04       Impact factor: 2.300

4.  Clinical manifestations of slow coronary flow from acute coronary syndrome to serious arrhythmias.

Authors:  Beata Wozakowska-Kapłon; Justyna Niedziela; Paweł Krzyzak; Sebastian Stec
Journal:  Cardiol J       Date:  2009       Impact factor: 2.737

5.  Relationship between neutrophil to lymphocyte ratio and slow coronary flow.

Authors:  Mehmet Doğan; Ahmet Akyel; Tolga Çimen; Murat Bilgin; Hamza Sunman; Haci Ahmet Kasapkara; Uğur Arslantaş; Kadriye Gayretli Yayla; Sadık Açıkel; Ekrem Yeter
Journal:  Clin Appl Thromb Hemost       Date:  2013-07-26       Impact factor: 2.389

6.  The relationship between eosinophilia and slow coronary flow.

Authors:  Yakup Altas; Ertugrul Kurtoglu; Baris Yaylak; Erkan Baysal; Berzal Ucaman; Hasan Murat Ugurlu; Mehmet Zülkif Karahan; Bernas Altintas; Mehmet Sahin Adiyaman; İlyas Kaya; Umut Erdolu; Kaya Ozen; Cayan Cakir; Utkan Sevuk
Journal:  Ther Clin Risk Manag       Date:  2015-08-12       Impact factor: 2.423

7.  Slow coronary flow phenomenon and increased platelet volume indices.

Authors:  Mir Hossein Seyyed-Mohammadzad; Kamal Khademvatani; Abdollah Kerachian; Ramin Eskandari; Yousef Rezaei
Journal:  Korean Circ J       Date:  2014-11-25       Impact factor: 3.243

8.  Cerebrolysin effects on neurological outcomes and cerebral blood flow in acute ischemic stroke.

Authors:  Mohammad Reza Amiri-Nikpour; Surena Nazarbaghi; Babak Ahmadi-Salmasi; Tayebeh Mokari; Urya Tahamtan; Yousef Rezaei
Journal:  Neuropsychiatr Dis Treat       Date:  2014-12-03       Impact factor: 2.570

9.  White Blood Cell Count to Mean Platelet Volume Ratio Is a Prognostic Factor in Patients with Non-ST Elevation Acute Coronary Syndrome with or without Metabolic Syndrome.

Authors:  Mohammad Reza Dehghani; Yousef Rezaei; Sanam Fakour; Nasim Arjmand
Journal:  Korean Circ J       Date:  2016-03-21       Impact factor: 3.243

10.  Mean platelet volume is not associated with coronary slow flow: a retrospective cohort study.

Authors:  Zekeriya Kaya; Özgür Günebakmaz; Ali Yıldız; Yusuf Sezen; Asuman Biçer Yeşilay; Emre Erkuş; Halil İbrahim Altıparmak; Recep Demirbağ
Journal:  Anatol J Cardiol       Date:  2014-04-02       Impact factor: 1.596

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.